Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(50.0%)

N/A

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 2(2)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06265051Phase 2Completed

Tirofiban After Successful MT Recanalization in AIS

Role: collaborator

NCT07459127Active Not Recruiting

Multicenter Retrospective Cohort of Pulmonary NUT Carcinoma

Role: lead

NCT07080437Recruiting

An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Role: lead

NCT07029464Not Yet Recruiting

Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis

Role: collaborator

NCT06766591Not ApplicableNot Yet Recruiting

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Role: collaborator

NCT05331651Phase 4Completed

Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting

Role: collaborator

NCT05810350Phase 2Unknown

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Role: lead

All 7 trials loaded